Occam Places Bryan Stuart as CEO of Atavistik
.jpg)
Atavistik, a computational biology platform company, and Lux Capital/Column Group investment, is focused on developing transformative small molecule therapeutics by revolutionizing the discovery and interrogation of new allosteric protein-metabolite interactions.
Bryan Stuart joins a formidable constellation of investors and operators, including Chairman John Josey, former CEO of Peloton Therapeutics which sold to Merck for over $1B, and Marion Dorsch, R&D heavyweight and former scientific leader at Blueprint and Agios.
Stuart was most recently CEO of Fulcrum, where he initially served as Chief Operating Officer. Prior to Fulcrum, he served as President and CEO of Yarra Therapeutics (a subsidiary of Array BioPharma) and CEO of Kastle Therapeutics. Previously, Stuart served as Chief Business Officer of Civitas Therapeutics (acquired by Acorda Therapeutics) and also led business development, corporate development, and strategy at both EKR Therapeutics (acquired by Chiesi Farmaceutici) and Ovation Pharmaceuticals (acquired by Lundbeck A/S).
Stuart earned his MBA from the Kellogg School at Northwestern University and his bachelor’s degree from the University of Illinois.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.